Clinical evaluation reports immunogenicity and safety profiles of extended-interval 9vHPV vaccination in adolescents, suggesting flexibility in two-dose immunization schedules.
Nine-valent human papillomavirus (9vHPV) vaccines can be administered in 2 doses 6 to 12 months apart in adolescents. The impact of extended dose intervals is unknown. We report immunogenicity and safety data in adolescents of a second 9vHPV vaccine dose administered ≥1 year after the first.
No takes yet. Share an insight, caveat, or question.
Klein et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: